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Abstract 
Cirobacter  freundii are currently standing  as a  newly emerged human pathogen causing several infection types 
.It may  take an outbreak pattern of  nosocomial  infectious disease. Thus,  a  prototype candidate Citrobacter  
freundii  human uro-pathogen were aimed to be  laboratory developed in two versions .The first  was heat killed 
intact[CFKV] and the second was  stealth live  cell wall defective[CFSLV] vaccines. Both versions were found 
to be; safe, immunogenic and effective  on  lapin immune and  challenge models. The immune efficacy was up 
to 80% for CF SLV and 60% for the CFKV vaccines. CFKV and CFSLV  vaccines  were with no mortality but 
with mild short lasting  morbidity. The criteria of the laboratory developed C. fruendii vaccines were matching 
that of typhoid vaccine Ty21a.The stealth FCSLV of  freundii vaccine has shown shared  antigenicity with 
CFKV vaccine version. Such shared antigenicity was found to be of bilateral nature  both in quantitative and 
qualitative terms. CFKV and CFSLV vaccines induced humoral antibody responses  which  may be of Th2 
dependent B cell responses. T cell responses are far from being operable in the immune  efficacy of these 
vaccines, since  C .fruendii are neither obligate nor facultative intracellular parasites . Vaccine lapin  cross 
challenge models  are waiting to be explored in a  future work. 
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1. Introduction  
The intact cell walled and the stealth cell wall defective  Citrobacter  freundii are evident emerging  
opportunistic  pathogen in general and uro-pathogen in particular. Their infection modes were as drug sensitive 
and multidrug resistant episodes [1,2,3,4].Hence, the interested  professionals were attracted  to develop   C. 
freundii  exo-polysaccharide  vaccine[5],cell free culture filtrate CFC vaccine[6,7].The objective of the  present 
communication was at: Developing a prototype candidate vaccines  in two versions. The intact heat killed 
CFKV and the stealth cell wall  defective CFSL , and  ii – Studying the  possible  sharing antigenicity of these  
two vaccine versions using agglutinin absorption studies. 
2. Material and Methods  
1.1 Vaccine Strain    
The vaccine strain of C .freundii  was an opportunistic  human  uro-pathogen as confirmed by classical 
andAPI20E[8]  . 
1.2 Laboratory Development 
Seed lot was prepared from a revived  strain  on brain heart infusion broth then onto brain heart infusion agar. 
Five identical  colony morpho-type were transferred  to nutrient broth and incubated for two hours at 37C. A 0.1 
ml from the two hours culture was used to seed the  50 ml medium in a flask and incubated at 37C for an 
overnight  period .The vaccine bacteria were checked for viability ,purity and found viable and pure .Then 
harvested by centrifugation at  
4000 rpm for five mints . The dosing was rated up to1.5x10 to eight  CFU/ml for CFKV. The final lot of the 
vaccine was dispensed at 2 ml. amounts and kept at4C for short term  experimentation. Growth in bulk for 
stealth   vaccine was made into high sucrose growth  medium in 50 ml .,flask containing  Impinim for 10 days at 
37C  then harvested by centrifugation at 5000 rpm for five mints and reconstituted by  sterile saline to the 
original cell density, and the dose matched  to 10 IU/ml. ,by    standard WHO Opacimeter   and made ready to 
specific immune priming of the Experimental rabbits[8,9]  as in the followings;  
Table 1: Animal Assignment 
Group   Vaccine Animals 
Group I CFKV 5 rabbits 
Group II CFKV 5 rabbits 
Group III saline 5 rabbits 
The test rabbits were adapted to the housing conditions for two weeks, checked for the presence of common 
pathogen antibodies in their sera and proved to be negative. The specific immune priming of these rabbit groups 
was the multisite multi injection protocol[10] ,using 1x10 to seven CFU/ml., for CFKV and 1o IU/ml., for 
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CFSLV live infectious doses. 
Table 2: The specific immune priming program of rabbits 
Priming Time Table[10] Dose Dosing Pattern 
First Week 
            First day 
            Second day 
2x 10 IU/ml. 
,one ml.  
1x10 IU/ml. 
,one ml. 
0.25 ml. SC in 
each of the 
four* para-
nodular areas 
Second week 
             First day 
             Second day 
2x10 IU/ml., 
one ml. 
1x10 IU/ml. 
,one ml. 
0.25 ml. SC  in 
each of the 
four para-
nodular areas 
Third week 
             First day 
             Second day 
1x10 IU /ml., 
one ml. 
1x10 IU/ml., 
one ml. 
0.25 ml. SC in 
each of the 
four para-
nodular areas 
Fourth week 
             First day 
             Second day 
Fifth week: Leave. 
Sixth week: test bled 
1x10 IU /ml., 
one ml. 
1x10 IU / ml., 
one ml. 
0.25 ml. SC in 
each of the 
four para-
nodular areas 
*Left and right sub-clavian  shoulder region; Left and right pelvic region. 
  SC= Subcutaneous  
1.3 Viability And Purity 
The viability checked by direct microscopy to watch motile rod phenotype and by plate viable count. Purity also 
checked by microscopic detection of contaminant phenotype in addition to quadrate streak culture to scan 
contaminating colony morpho-types. 
 
1.4 Immunogenicity 
The immunogenicity of the vaccines was checked through agglutination  studies of vaccine and lapin immune 
sera[10,11,12]. 
1.5 Efficacy  
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The efficacy in the lapin challenge model was measured as  ;vitality, morbidity and mortality percentages of the 
challenged rabbits( 12 ). 
1.6 Safety 
Gross signs of primed morbid animals for toxic unsafe changes observed  on evisceration  ,if any, will be 
checked histologically[11,12]. 
1.7 Shared Antigenicity  
Shared antigenicity was detected using agglutinin cross-absorption studies[ 13,14,15 ]. 
3. Results  
3.1 Laboratory Development 
The  in-vitro  developmental evaluations criteria have shown that the vaccine bacteria in both  vaccine versions 
were viable  and pure. The in-vivo evaluation criteria were showing that the proto-type candidate vaccines were 
;pure ,safe, immunogenic and effective in lapin challenge  models. The immunogenicity of the CFKV vaccine 
was  to the  titre of  11946 While the immunogenicity of CFSLV vaccine was to the titre of 16936.The efficacy 
was up to 80% in case of  CFSLV vaccine and of 60% for the  CFKV  vaccine .The two prototype vaccine  
versions are compared to the laboratory developmental criteria of Ty21a vaccine of Salmonella typhi ,Tables  3, 
4 and 5. 
Table 3: The immunogenicity of the two  C. fruendii vaccine versions 
Immune-sera/vaccine antigens Titre* 
Polyclonal anti-CFKV 11946 
Polyclonal anti-CFSLV 16936 
  
*Mean of five readings 
Table 4: The immune efficacy of the two C.fruendii  prototype vaccine versions 
Immune-sera/vaccine antigens Vitality Morbidity Mortality 
Intact heat killed CFKV  3:5*(60%) 2:5(40%). 0:5(0%) 
Stealth Cell wall defective CFSLV 4:5(80 % ) 1:5(20% ) 0:5(0%) 
    
*Number  of test rabbits 
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Table 5: The developmental  criteria  of C .freundii prototype vaccines 
Immune-sera/vaccine antigens Stealth CFSV Intact CFKV Ty21a* 
Understanding the disease Understandable Understandable Understandable 
Understanding the causal Understandable Understandable Understandable 
Preparing prototype candidate vaccine 
and laboratory preclinical evaluations 
Safety 
Dosing 
Viability 
Purity 
Immunogenicity 
Efficacy 
 
Safe 
Ratified 
 Non-viable 
Pure 
Immunogenic 
Effective to 
80% 
 
Safe 
Ratified 
Nonviable 
Pure 
Immunogenic 
Effective to 
60% 
 
Safe 
Ratified 
Live attenuated 
Pure 
Immunogenic 
Effective to 
90% 
*Based on [16]. 
3.2 Shared Antigenicity 
The  polyclonal  unabsorbed antiserum ASIII when reacted with the antigen AGI gave a mean  titre of 2139 but 
when reacted with AGII gave a mean titre of 1523.Homologous antigen-antibody reaction showed higher 
agglutinin titres than the heterologous antigen- antibody reactions. The absorption, and the reciprocal  cross-
absorption studies have shown that the ASV when reacted with the vaccine AGII gave a mean titre of 226,while 
when reacted with vaccine AGI gave a mean titre of 13  while  when  ASII  reacted with AGI it also gave mean 
titre of 13.Absorption of polyvalent antisera  with their homologous vaccine reduce but not diminish  the 
antibody titres. Reciprocal  cross-absorption  of the polyclonal antisera revealed low titres with homologous 
vaccines and  near diminished with heterologous  vaccines, Tables 6 and 7.The results indicated that there were 
shared antigenicity between the two vaccine versions of C .fruendii, in a bilateral manner and both in 
quantitative and qualitative terms. 
Table 6: Designations of Antisera and Vaccines 
Entity Description Nature Designation 
Antiserum Polyclonal anti-intact Non-absorbed ASI 
 Polyclonal anti-intact Absorbed  with stealth vaccine ASII 
 Polyclonal anti-intact Absorbed with intact ASIII 
 Polyclonal anti-stealth Non-absorbed ASIV 
 Polyclonal  anti-stealth Absorbed with stealth ASV 
 Polyclonal anti-stealth Absorbed with  intact AS VI 
Vaccines Intact heat killed 
Stealth cell wall defective 
 AGI 
AGII 
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Table 7: Agglutination Assays of the vaccine versions and their antisera ,showing the shared antigenicity 
Reaction Assay Type 
Anti-Intact-
Intact CFKV 
Titre Assay Type 
Anti-stealth-
Stealth CFSLV 
Titre 
Reaction ASI+AGI  11946 ASIV +AGII  16963 
Cross reaction ASI+AGII 1523 ASIV+ AGI 2139 
Absorption ASII+AGII 46 ASV+AGII 226 
Cross-Absorption ASIII+AGI 13 ASVI+AGI 13 
     
 
4. Discussion  
C. freundii as a human opportunistic  uro-pathogen  have  several virulence factors  like ;fimbrae ,toxins ,outer-
membrane proteins, porins, lipoproteins and lipopolysaccharides [17].They are involved in 14-18% of clinical 
human  cystitis  cases[18] .  It has been reported that C.freundii  are currently emerging  human uropathogen  in 
an opportunistic  mode of infection and it may took outbreak episode  forms( 1,2,3,4.19].The aforementioned 
situation forms good initiative for development of  C. freundii vaccines[5,19]. 
Both of CFKV and CFSLV prototype vaccines were found pure, safe and immunogenic in rabbits models as 
well as they are with efficacy limits between 60 to 80   as lapin challenge model experiment have shown,  the 
author in [5] have shown 90% efficacy in murine model  using exo-polysaccharide vaccine .They express no 
mortality and mild urethral  morbidity. The gained immunity from  CFKV,CFSLV immunization in rabbits may 
be mediated by TH2-B lymphocyte cell-cell activation leading to humoral antibody responses rather than Th1 
mediated immunity . Since  C .freundii are neither  obligate nor facultative intracellular pathogen[19]. Shared 
antigenicity of CFKV and CFSLV vaccines were found to be of  major   quantitative  and minor qualitative 
nature as reciprocal cross-agglutinin assays indicated using  vaccine primed lapin immunesera  and prototype 
vaccine candidate antigens[20,21]. Stealth vaccine epitope(s) was potent agglutinin absorbers than that of intact 
vaccine epitope(s)[22].This difference may be attributed to their higher affinities of reaction with the available 
paratope in the prepared lapin sera[ 23]. This lapin  challenge model was  of promising results concerning the 
laboratory development of these two  prototype vaccine versions of C. freundii ,but need to be confirmed in 
other nonhuman primate model before the initiation of clinical development.  Since, the immune response  to the 
vaccines   in  nonhuman vertebrate(lapin model) are  different from that of human being immune response[24].  
5. Conclusion 
These two candidate C .freundii vaccines were proved to be pure, safe ,immunogenic ,and of 60 to 80% efficacy 
in lapin models but they are still in need for proving their development  in lapin cross –challenge model  and  in 
non-human primate model. 
International Journal of Sciences: Basic and Applied Research (IJSBAR)(2019) Volume 43, No  1, pp 22-29 
28 
 
6. Recommendation 
The authors are of the opinion that the next step is to put-forward the laboratory development of these prototype 
vaccines in non-human primate model.    
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